Full-Time

Director – Pipeline Strategy

Confirmed live in the last 24 hours

Arcellx

Arcellx

51-200 employees

Develops immunotherapies for cell therapy

Biotechnology
Healthcare

Compensation Overview

$230k - $255kAnnually

+ Annual Bonus + Equity Grant

Senior, Expert

San Carlos, CA, USA

Relocation assistance offered if required.

Category
Computational Biology
Biology Lab & Research
Biology & Biotech
Requirements
  • PhD or MD with 8+ years of industry experience.
  • Expertise in developing immunotherapies for cancer.
  • Broad understanding of the evolving clinical and global commercial landscape in oncology, autoimmune and inflammatory diseases, and cell therapy.
  • Outstanding strategic planning and analytical skills with the ability to synthesize findings and articulate implications from multiple sources of information to formulate strong recommendations and uncover market opportunities.
  • Mastery of project management tools and timeline management.
  • Demonstrated experience leading at scale, motivating teams, and influencing senior leaders and key stakeholders.
  • Ability to take initiative, build productive relationships, work cross-functionally, and manage multiple projects.
Responsibilities
  • Accountable for developing and driving project strategy with scientific rigor in alignment with portfolio strategy.
  • Manage the project timeline and budget across cross-functional workstreams, ensuring alignment of key deliverables, anticipating and mitigating risks, and driving accountability across the organization.
  • Partner with functional leads to support CMC development and commercialization activities and ensure adequate clinical supply for the early and late-stage portfolio.
  • Identify, develop, articulate, and present strategic options to make the best trade-off decisions within a project (e.g., technical product profile alterations, clinical product considerations) and across the portfolio as needed given changing market conditions or key early-stage data outputs.
  • Present critical program updates for data read-outs or notable preclinical / clinical milestones to senior leadership.
  • Ensure appropriate visibility to the organization on timeline, progress-to-date, upcoming key milestones, and identified risks.
  • Escalate and resolve key issues with the senior management team.

Arcellx develops immunotherapies aimed at improving cell therapy for serious diseases. Their products focus on advanced techniques that enhance the body's immune response to fight illnesses. The company collaborates with healthcare providers and research institutions to bring these therapies to patients. Unlike many competitors, Arcellx emphasizes proprietary products and partnerships to drive their research and development efforts. The main goal is to meet unmet medical needs by providing safe and effective treatment options through their innovative approach to cell therapy.

Company Stage

IPO

Total Funding

$194.5M

Headquarters

Gaithersburg, Maryland

Founded

2014

Growth & Insights
Headcount

6 month growth

5%

1 year growth

22%

2 year growth

61%
Simplify Jobs

Simplify's Take

What believers are saying

  • Strategic partnership with Kite accelerates development and commercialization of therapies.
  • FDA support expedites approval process for Arcellx's innovative treatments.
  • Advancements in gene editing enhance precision of Arcellx's cell therapies.

What critics are saying

  • Competition from established CAR-T therapies like Abecma and Carvykti.
  • Dependency on Kite partnership could pose risks if dynamics change.
  • Phase 3 trial for anito-cel carries risk of not meeting endpoints.

What makes Arcellx unique

  • Arcellx's CART-ddBCMA has FDA Fast Track, Orphan Drug, and RMAT designations.
  • The ARC-SparX platform offers dosable and controllable CAR-T therapy options.
  • Anito-cel uses a novel D-Domain BCMA binder for enhanced antigen binding.

Help us improve and share your feedback! Did you find this helpful?